• Peer-reviewed data published in Neurosurgery show that SOLOPASS^® 2.0 delivers significantly higher accuracy than free-hand EVD placement.

• SOLOPASS^® 2.0 achieved consistent accuracy across all clinician experience levels.

inTRAvent Medical Partners LP, a pioneer in bedside, image-guided neurosurgical innovation, today announced the publication of a peer-reviewed study in Neurosurgery evaluating the accuracy of external ventricular drain (EVD) placement using its ultrasound-guided neuronavigation platform, SOLOPASS^® 2.0.

The study, “Evaluation of a Novel, Bedside, Ultrasonographic Neuronavigation System Versus Free-Hand Ventricular Targeting: A Double-Blinded, Prospective, Paired Comparison Study,”¹ showed that the SOLOPASS^® 2.0 System delivered substantial improvements in placement accuracy and potential safety compared with traditional freehand techniques. It was published Nov. 13, 2025 in Neurosurgery.

In a prospective, double-blinded, repeated-measures experiment, 25 participants ranging from first-year medical students to attending neurosurgeons performed simulated EVD placements using both conventional freehand techniques and SOLOPASS^® 2.0 ultrasound-guided neuronavigation techniques on anatomically realistic, life-sized cranial models.

Key Findings:

• 98% of placements using SOLOPASS^® 2.0 entered the ventricular system, versus only 10% of freehand placements.

• 86% of placements using SOLOPASS^® 2.0 accurately reached the ipsilateral frontal horn target, compared to only 8% with freehand techniques (P < 0.001).

• The mean miss margin was less than 0.5mm using SOLOPASS^® 2.0, compared to nearly 8mm using freehand guidance (P < 0.001).

• SOLOPASS^® 2.0 consistently delivered superior first-pass accuracy across all levels of neurosurgical experience, demonstrating consistent performance regardless of operator skill.

“These findings highlight the transformative potential of ultrasound-guided neuronavigation for safer, more precise ventricular access,” said Dr. Kevin Foley, inTRAvent’s Chief Innovation Officer. “SOLOPASS 2.0^® empowers clinicians at every experience level to achieve accurate ventricular placement by delivering real-time imaging on an intuitive, easy-to-use platform—an essential advancement for neurosurgical and critical care patients alike.”

“In modern medicine, quality and safety are paramount,” said Dr. Adam Arthur, Chief Clinical Strategy Officer. “The study reinforces our commitment to advancing real-time image guidance and precision in neurosurgery. By integrating portable ultrasound into bedside ventricular procedures, inTRAvent aims to reduce complications, improve outcomes, and expand the accessibility of high-precision care across the spectrum of clinical settings.”

About inTRAvent Medical Partners

inTRAvent Medical Partners is a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve the safety and efficacy of neurosurgical procedures. The Company’s FDA Cleared SOLOPASS^® platform enables simple, portable neuro-navigation using 2D and 3D ultrasound imaging, artificial intelligence, and trajectory guidance for intra-procedural localization and navigation. For more information, please visit www.inTRAventMedical.com, or find us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251118971409/en/